Home | Structured Search | Drug Resource
Find: within
Anthrax > Prevention Author: Sandro Cinti, MD; Barbara Robinson-Dunn, PhD; Niklas Mackler, MD
Module updated - 2009-11-19
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Preexposure vaccination protects against cutaneous and inhalational anthrax.
  • Anthrax vaccine is safe, but side effects include local reactions, fever, chills, and body aches.

Evidence:

  • Animal and human studies support the efficacy of anthrax vaccine for prevention of inhalational and cutaneous anthrax (1; 2; 3; 4; 5; 6).
  • The basis for the six initial vaccine doses followed by yearly boosters is not well defined (7).
  • Mild cutaneous reactions occur in 20% of patients vaccinated, whereas severe local reactions and systemic reactions occur in <=1% (1; 8; 9).
  • Although no adverse birth outcomes occurred in a recent study, the evidence for use of anthrax vaccine in pregnancy is not conclusive (8; 10).
  • Contraindications to anthrax vaccine include history of anthrax infection or anaphylaxis to a previous dose of anthrax vaccine (8).
  • There was no evidence for an unusual rate of any severe adverse event or other medically important adverse events in more than 500,000 military personnel vaccinated against anthrax (11).
  • A study of U.S. Army personnel who received >=1 dose of AVA between March 1998 and February 2002 showed that this group had no greater risk of disability than those who had not received AVA (12).
  • Assessment of the first 1005 subjects enrolled in a multisite, randomized, double-blind, noninferiority, phase 4 human clinical trial of AVA showed that subjects who received three or four intramuscular doses of AVA over 6 months had the same antibody responses at 7 months as those who received the standard schedule of four subcutaneous doses in the first 6 months. Intramuscular administration of AVA also resulted in fewer side effects at the injection site as compared to subcutaneous injection (13).

Comments:

  • AVA (BioThrax®, Emergent BioSolutions) is the only licensed human vaccine for anthrax in the U.S.

FAQs
Barbara Robinson-Dunn, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Nicholas John Vietri, MD, MS, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Niklas Mackler, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sandro Cinti, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for continuing medical education grand rounds and lectures given.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.